Ligand Raises FY26 EPS Guidance as Royalty Revenue Soars 51%

What happened

Ligand reported third-quarter 2026 royalty revenue of $70.3 million, up 51% year-over-year, and raised full-year adjusted diluted EPS guidance to $9.50-$9.75 from $9.00-$9.50, while reaffirming revenue guidance. The strong royalty growth confirms the company's ongoing momentum from key products like FILSPARI and Ohtuvayre, but the master report had already priced in a successful 2026 royalty step-up, with the stock trading at $198.58 and a P/E of 78.9x. The raised EPS guidance is a positive signal, but it primarily reflects higher royalty income and possibly operational leverage; however, the company's revenue guidance remains unchanged, suggesting limited upside surprise on the top line. Given the high valuation and concentration risk in a few royalty streams, the market reaction may be muted as investors await further confirmation of sustained FILSPARI demand and Ohtuvayre performance under Merck. The master report's base case implied value of $205 is only slightly above the current price, and with the stock near its trim threshold, the risk-reward remains unattractive for new buyers unless there is a pullback.

Implication

The Q3 report validates the royalty growth trajectory but fails to address the key uncertainty around the sustainability of FILSPARI's record patient start forms and the visibility of Ohtuvayre under Merck. With the stock priced at approximately $198 and a forward P/E near 79x, the market already embeds a high degree of optimism, leaving little room for error if either key royalty driver disappoints. The reaffirmed revenue guidance suggests management is not seeing upside to the top line beyond prior expectations, which may temper enthusiasm among growth investors. For existing holders, the raised EPS guidance provides some support, but the risk-reward at current levels favors trimming positions above $225 as indicated in the master report, while waiting for a pullback toward $175 before adding. Investors should monitor upcoming partner updates, particularly Travere's FILSPARI prescription trends and any signals from Merck regarding Ohtuvayre, as these will determine whether the royalty growth remains on track to justify the premium valuation.

Thesis delta

The Q3 results and raised EPS guidance do not materially alter the investment thesis; the company continues to execute on its royalty aggregation strategy, but the stock remains fully valued. The master report's WAIT rating and $205 base case are unchanged, as the news reinforces existing expectations rather than introducing new upside. The key swing factors remain the same: FILSPARI demand sustainability and Ohtuvayre disclosure.